3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Ovarian Neoplasms
15
Fallopian Tube Neoplasms
13
Lung Neoplasms
11
Melanoma
8
Colorectal Neoplasms
8
Glioblastoma
7
Carcinoma, Non-Small-Cell Lung
7
Carcinoma, Hepatocellular
7
Urinary Bladder Neoplasms
6
Carcinoma, Renal Cell
6
Uterine Cervical Neoplasms
4
Triple Negative Breast Neoplasms
4
Pancreatic Neoplasms
4
Lymphoma, Large B-Cell, Diffuse
4
Brain Neoplasms
4
Rectal Neoplasms
3
Prostatic Neoplasms
3
Neoplasm Metastasis
3
Nasopharyngeal Carcinoma
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Breast Neoplasms
3
Uveal Melanoma
2
Thyroid Neoplasms
2
Small Cell Lung Carcinoma
2
Sarcoma
2
Oligodendroglioma
2
Multiple Myeloma
2
Medulloblastoma
2
Lymphoma, B-Cell
2
Lymphoma
2
Interventions
Paclitaxel
6
Doxorubicin
6
Gemcitabine
4
Bevacizumab
4
pembrolizumab
3
pazopanib
3
durvalumab
3
Sorafenib
3
Docetaxel
3
trebananib
2
spartalizumab
2
cemiplimab
2
brostallicin
2
Propranolol
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Ipilimumab
2
Imatinib Mesylate
2
Ifosfamide
2
Carboplatin
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
tremelimumab
1
trastuzumab duocarmazine
1
temsirolimus
1
talimogene laherparepvec
1
talazoparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Hemangiosarcoma
×
Disulfides
×
Clear all
NCT04668300
2026-04-15
DOSa
M.D. Anderson Cancer Center
Phase 2
Active not recruiting
75 enrolled